Signal

New studies reveal molecular and clinical heterogeneity in cardiovascular and metabolic syndromes

Evidence first: scan the strongest sources, then decide whether to go deeper.

Published 2026-06-18 23:00 UTCUpdated 2026-06-19 02:57 UTC
rss
clinical_trialsdrug_developmentsafety_signalsgenomicsr_and_d
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (1 domains)domains are deduped. counts indicate coverage, not truth.
1 top source shown
limited source diversity in top sources
Overview

Recent large-scale studies highlight the complex molecular and clinical heterogeneity underlying cardiovascular disease and mortality risk.

Entities
Yang, Y.Tan, D.Carrasco-Zanini, J.Su, C.-Y.Zhou, S.Koyama, S.Natarajan, P.Langenberg, C.
Score total
0.72
Momentum 24h
2
Posts
2
Origins
1
Source types
1
Duplicate ratio
0%
Why now
  • Large-scale proteomic and epidemiological datasets now enable discovery of novel predictive biomarkers.
  • Rising burden of cardiovascular-kidney-metabolic syndromes demands improved prognostic tools.
  • Integration of multi-dimensional biomarkers is a frontier in precision cardiometabolic medicine.
Why it matters
  • Improved molecular and physiological markers enable better risk stratification for cardiovascular diseases.
  • Understanding heterogeneity supports development of targeted interventions and personalized medicine.
  • Cross-cohort validation enhances confidence in biomarkers across populations.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
  • A 320-protein plasma panel improves prediction of incident coronary artery disease beyond traditional clinical risk scores.
  • Combined indices of inflammation, metabolic markers, frailty, and cardiorespiratory fitness predict all-cause and cardiovascular mortality in adults with cardiovascular-kidney-metabolic syndrome.
How sources frame it
  • Yang Et Al.: neutral
  • An Et Al.: neutral
This narrative synthesizes recent preprints that advance understanding of cardiovascular disease heterogeneity through proteomics and integrated clinical indices, highlighting opportunities for precision medicine.
All evidence
Show filters & breakdown
Posts loaded: 0Publishers: 1Origin domains: 1Duplicates: -
Showing 1 / 0
Top publishers (this list)
  • medRxiv (all subjects) (1)
Top origin domains (this list)
  • medrxiv.org (1)